Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;29(8):387-94.
doi: 10.1111/j.1365-3024.2007.00951.x.

Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3

Affiliations

Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3

F H A Osier et al. Parasite Immunol. 2007 Aug.

Abstract

Many studies on the role of merozoite surface protein 3 (MSP3) in immunity against malaria have focused on a conserved section of MSP3. New evidence suggests that polymorphic sequences within MSP3 are under immune selection. We report a detailed analysis of naturally-acquired antibodies to allele-specific and conserved parts of MSP3 in a Kenyan cohort. Indirect and competition ELISA to heterologous recombinant MSP3 proteins were used for antibody assays, and parasites were genotyped for msp3 alleles. Antibody reactivity to allele-specific and conserved epitopes of MSP3 was heterogeneous between individuals. Overall, the prevalence of allele-specific antibody reactivity was significantly higher (3D7-specific 54%, K1-specific 41%) than that to a recombinant protein representing a conserved portion of C-terminal MSP3 (24%, P < 0.01). The most abundant IgG subclass was IgG3, followed by IgG1. Allele-specific reactivity to the K1-type of MSP3 was associated with a lower risk of clinical malaria episodes during a 6-month follow-up in individuals who were parasitized at the start of the malaria transmission season (Relative risk 0.41 with 95% confidence interval 0.20-0.81, P = 0.011). The potential importance of allele-specific immunity to MSP3 should be considered in addition to immunity to conserved epitopes, in the development of an MSP3 malaria vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation between antibody reactivity to K1 MSP3 and 3D7 MSP3 in the sera of 536 individuals from Chonyi village. Dashed lines indicate cut-off values for positive reactivity for 3D7 and K1 MSP3, respectively, as determined by mean + 3 SD of reactivity of 20 non-malaria exposed controls. Pair wise correlation coefficient was 0·6752, P = 0·0000, n = 536.
Figure 2
Figure 2
Competition ELISA using titred amounts of competing antigen on six representative sera. Data on remaining 14 sera are shown in supplementary figures.
Figure 3
Figure 3
Age-specific prevalence of anti-MSP3 antibodies. Numbers above each group of bars indicate the number of individuals in each age category. The presence of allele-specific reactivity to 3D7 and K1 MSP3 was determined as follows: samples that were sero-positive (serum IgG OD level above the mean + 3 SD of that of 20 non-malaria exposed sera) for 3D7 MSP3 and sero-negative for K1 MSP3 were considered to be allele-specific for 3D7-MSP3, and likewise for K1 MSP3; samples that were sero-positive for both 3D7 and K1 MSP3 were tested by competition ELISA and differences of > 0·3 OD units between the heterologous and homologous competition assays were counted as evidence of allele-specific reactivity. Samples were considered to be positive for C-terminal MSP3 if the serum IgG OD level was above the mean + 3 SD of that of 20 non-malaria exposed sera.
Figure 4
Figure 4
(a, b) IgG subclass reactivity to MSP3 recombinant antigens, (a) 3D7 MSP3 and (b) K1 MSP3, respectively. Horizontal bars indicate means (n = 96).

Similar articles

Cited by

References

    1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005;434:214–217. - PMC - PubMed
    1. Marsh K. Malaria – a neglected disease? Parasitology. 1992;104(Suppl):S53–S69. - PubMed
    1. Tongren JE, Zavala F, Roos DS, Riley EM. Malaria vaccines: if at first you don't succeed. Trends Parasitol. 2004;20:604–610. - PubMed
    1. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990;172:1633–1641. - PMC - PubMed
    1. Cohen S, McGregor IA, Carrington S. γ-globulin and acquired immunity to human malaria. Nature. 1961;192:733–737. - PubMed

Publication types

MeSH terms